Contemporary platelet function testing

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 5, 2010, Pages 579-598

  Favaloro, Emmanuel J ^a   Lippi, Giuseppe ^b   Franchini, Massimo ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Aggregometry; PFA 100; Platelet function; Review

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CALCIMYCIN; CLOPIDOGREL; COLLAGEN; COLLAGEN RECEPTOR; CONVULXIN; INDOMETACIN; MELOXICAM; MEMBRANE RECEPTOR; RISTOCETIN; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE ACTIVATING FACTOR; TICLOPIDINE; VON WILLEBRAND FACTOR;

BERNARD SOULIER DISEASE; BLOOD CELL COUNT; BLOOD CLOTTING PARAMETERS; CELL COUNT; CELL ORGANELLE; CHEDIAK HIGASHI SYNDROME; DIAGNOSTIC PROCEDURE; DRUG MONITORING; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GENETIC ANALYSIS; GLANZMANN DISEASE; GRAY PLATELET SYNDROME; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LUMIAGGREGOMETRY; OCULAR ALBINISM; PRIORITY JOURNAL; PROTEOMICS; QUALITY CONTROL; QUEBEC PLATELET DISORDER; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOELASTOGRAPHY; VON WILLEBRAND DISEASE; WHOLE BLOOD AGGREGOMETRY; WISKOTT ALDRICH SYNDROME;

BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; MEMBRANE PROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; QUALITY CONTROL; VON WILLEBRAND DISEASES;

EID: 77952506357     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.121     Document Type: Review

References (87)

1. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009;35:9-22.
2. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45:2-12.
3. Favaloro EJ. Towards a new paradigm for the identification and functional characterisation of von Willebrand disease. Semin Thromb Hemost 2009;35:60-75.
4. Quiroga T, Goycoolea M, Panes O, Aranda E, Martínez C, Bel-mont S, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007;92:357-65.
5. Favaloro EJ. Investigating people with mucocutaneous bleeding suggestive of primary haemostatic defects: low likelihood of definitive diagnosis? Haematologica 2007;92:292-6.
6. Pereira J, Quiroga T, Mezzano D. Laboratory assessment of familial, nonthrombocytopenic mucocutaneous bleeding: a definitive diagnosis is often not possible. Semin Thromb Hemost 2008;34:654-62.
7. Mezzano D, Quiroga T, Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost 2009;35:242-54.
8. Franchini M, Lippi G, Veneri D, Targher G, Zaffanello M, Gui-di GC. Inherited platelet disorders. Clin Chim Acta 2008;387:1-8.
9. Harrison P, Goodall AH. "Message in the platelet" - more than just vestigial mRNA! Platelets 2008;19:395-404.
10. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009;35:150-7.
11. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009;35:189-203.
12. Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007;44:115-49.
13. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemor-rahagic disease relieved by blood transfusion. J Am Med Assoc 1910;55:1185-92.
14. Ivy AC, Nelson D, Buchet C. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med 1941;26:1812-22.
15. Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 2009;405:8-16.
16. Adams M, Ward C, Thom J, Bianchi A, Perrin E, Coghlan D, et al. Emerging technologies in hemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Semin Thromb Hemost 2007;33:226-34.
17. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ost-gaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-12.
18. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(Suppl 2):113-21.
19. ™. Clin Appl Thromb Hemost 1996;2:241-9.
20. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-33.
21. Lippi G, Franchini M, Brocco G, Manzato F Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369-70.
22. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32:537-45.
23. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670.
24. Favaloro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, et al. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coagul Fibrin 2009;20:475-83.
25. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-11.
26. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cer-letti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA) -100. A systematic review. Thromb Haemost 2008;99:14-26.
27. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6:444-50.
28. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3003 patients. Thromb Haemost 2008;99:1129-31.
29. Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009;102:719-27.
30. Kilanowska J, Favaloro EJ, Lippi G Aspirin 'responsiveness', 'non-responsiveness' or 'resistance': a putative role for von Willebrand factor? Blood Coagul Fibrin 2008;19:823-4.
31. Favaloro EJ, Mohammed S. Platelet function testing: auditing local practice and broader implications. Clin Lab Sci 2010;23:21-31.
32. Wallin O, Söderberg J, Grankvist K, Jonsson PA, Hultdin J. Preanalytical effects of pneumatic tube transport on routine hae-matology, coagulation parameters, platelet function and global coagulation. Clin Chem Lab Med 2008;46:1443-9.
33. Lippi G, Manzato F, Franchini M, Brocco G, Florenziani G, Guidi G. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001;1:69-70. (Pubitemid 32972413)
34. Born GV. Aggregation of blood platelets by adenosine diphos-phate and its reversal. Nature 1962;194:927-9.
35. O'Brien JR. Platelet aggregation: part II, some results from a new method of study. J Clin Pathol 1962;15:452-5.
36. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-67.
37. CLSI. Platelet function testing by agggregometry; approved guideline. CLSI document H58-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
38. Pai M, Hayward C. Diagnostic assessment of platelet disorders: what are the challenges to standardization? Semin Thromb Hemost 2009;35:131-8.
39. Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, et al. Diagnostic utility of light transmission platelet aggre-gometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009;7:676-84.
40. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694-7.
41. Mani H, Luxembourg B, Kläffling C, Erbe M, Lindhoff-Last E. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005;58:747-50.
42. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. North American Specialized Coagulation Laboratory Association. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:549-53.
43. Duncan EM, Bonar R, Rodgers SE, Favaloro EJ, Marsden K. RCPA QAP in haematology, haemostasis committee. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. Int J Lab Hematol 2009;31:398-406.
44. Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008;61:950-4.
45. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009;7:1029.
46. Favaloro EJ. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost 2009;35:139-49.
47. McGlasson D, Fritsma G. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009;35:168-80.
48. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980;3:135-58.
49. Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood lumiaggrego-meter. Thromb Haemost 1984;51:154-6.
50. Plebani M, Sanzari MC, Zardo L. Quality control in coagulation testing. Semin Thromb Hemost 2008;34:642-6.
51. Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33:273-82.
52. Favaloro EJ, Bonar R, Duncan E, Rodgers S, Marsden K (on behalf of the RCPA QAP in Haematology). The utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand. Blood Coagul Fibrin 2007;18:441-8.
53. Hayward CP, Moffat KA, Spitzer E, Timleck M, Plumhoff E, Israels SJ, et al. Results of an external proficiency testing exercise on platelet dense granule deficiency testing by whole mount electron microscopy. Am J Clin Pathol 2009;131:671-5.
54. Miller JL. Glycoprotein analysis for the diagnostic evaluation of platelet disorders. Semin Thromb Hemost 2009;35:224-32.
55. Nurden AT, Caen JP. Specific roles for platelet surface glyco-proteins in platelet function. Nature 1975;255:720-2.
56. Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G, Levy-Toledano S, et al. Bernard-Soulier syndrome. A new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 1976;87:586-96.
57. Phillips DR, Agin PP. Platelet membrane defects in Glanz-mann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977;60:535-45.
58. Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007;33:771-9.
59. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008;34:683-91.
60. Blann A, Shantsila E, Shantsila A. Microparticles and arterial disease. Semin Thromb Hemost 2009;35:488-96.
61. Clauser S, Cramer-Bordé E. Role of platelet electron microscopy in the diagnosis of platelet disorders. Semin Thromb Hemost 2009;35:213-23.
62. Senzel L, Gnatenko DV, Bahou WF. Genomic and proteomic applications in diagnosis of platelet disorders and classification. Semin Thromb Hemost 2008;34:532-8.
63. Curtis BR. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost 2008;34:539-48.
64. Nurden AT, Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders. Semin Thromb Hemost 2009;35:204-12.
65. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010;411:1-6.
66. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628-36.
67. Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med 2007;131:1834-6.
68. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008;34:113-27.
69. Kannan M, Saxena R. Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost 2009;15:152-65.
70. Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin Thromb Hemost 2007;33:780-6.
71. Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 2008;30:90-4.
72. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985;318:470-2.
73. Meyer M, Kirchmaier CM, Schirmer A, Spangenberg P, Strohl C, Breddin K. Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein IIb-IIIa complex-1. Glycoprotein analysis. Thromb Haemost 1991;65:491-6.
74. Campo G, Valgimigli M, Gemmati D. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 2006;48:2178-85.
75. Remold-O'Donnell E, Rosen FS, Kenney DM. Defects in Wis-kott-Aldrich syndrome blood cells. Blood 1996;87:2621-31.
76. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390-8.
77. Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloprolifer-ative disorders. J Cell Mol Med 2001;5:79-87.
78. Zeidman A, Sokolover N, Fradin Z, Cohen A, Redlich O, Mit-telman M. Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 2004;5:234-8.
79. Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 1987;70:620-3.
80. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007;21:21-36.
81. Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrin 2008;19:109-19.
82. Frenkel EP, Mammen EF. Sticky platelet syndrome and throm-bocythemia. Hematol Oncol Clin North Am 2003;17:63-83.
83. Mühlfeld AS, Ketteler M, Schwamborn K, Eitner F, Schneider B, Gladziwa U, et al. Sticky platelet syndrome: an underreco-gnized cause of graft dysfunction and thromboembolic complications in renal transplant recipients. Am J Transplant 2007;7:1865-8.
84. Mammen EF. Sticky platelet syndrome. Semin Thromb Hemost 1999;25:361-5.
85. Hackam DG, Eikelboom JW. Antithrombotic treatment for peripheral arterial disease. Heart 2007;93:303-8.
86. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and post-analytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008;34:612-34.
87. Israels SJ. Diagnostic evaluation of platelet function disorders in neonates and children: an update. Semin Thromb Hemost 2009;35:181-8.